| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K17060750 | CTRPv2 | pan-cancer | AAC | -0.027 | 0.5 |
| mRNA | ML083 | CTRPv2 | pan-cancer | AAC | -0.028 | 0.5 |
| mRNA | PL-DI | CTRPv2 | pan-cancer | AAC | 0.022 | 0.5 |
| mRNA | masitinib | CTRPv2 | pan-cancer | AAC | -0.026 | 0.5 |
| mRNA | avrainvillamide | CTRPv2 | pan-cancer | AAC | -0.029 | 0.5 |
| mRNA | TG-100-115 | CTRPv2 | pan-cancer | AAC | -0.026 | 0.5 |
| mRNA | BRD-K90370028 | CTRPv2 | pan-cancer | AAC | 0.039 | 0.5 |
| mRNA | tretinoin:navitoclax (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.024 | 0.5 |
| mRNA | AZD1480 | CTRPv2 | pan-cancer | AAC | -0.038 | 0.5 |
| mRNA | BMS-754807 | CTRPv2 | pan-cancer | AAC | -0.024 | 0.5 |